Loading
A phase 2 trial of ADG126 and pembrolizumab in colorectal cancer, run by National University Hospital, Singapore, now recruiting.
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT06846268 by National University Hospital, Singapore, with a registry enrolment figure of 20 participants, started 2025-04-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: ADG126; Pembrolizumab. Conditions listed: Locally Advanced Colorectal Cancer. Primary outcome: Rate of Major Pathologic Response (MPR). Colorectal eligibility wording from the registry: "Histologically confirmed colorectal adenocarcinoma". Sites: Singapore. No results are recorded here; the registry entry is the source.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.